Clinical Trial

FDOPA PET and Nutritional Support in Parkinson's Disease

Study acronym: FdopaPD2
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The overall goal of this study will be to further our understanding of how N Acetyl Cysteine (NAC) can help to support dopaminergic function in patients with Parkinson's disease (PD). We plan to use pre and post Positron emission tomography magnetic resonance imaging (PET-MRI) with \[F-18\] Fluorodopa (FDOPA) to measure dopamine function, and neurological measures to assess clinical symptoms, in patients with PD who are given oral capsules plus IV infusions of NAC in addition to standard of care for PD for 6 ±3 months in an open label cross over design. Serum measures of NAC concentrations, magnetic resonance spectroscopy (MRS) to measure inflammatory and oxidative stress markers, may be conducted.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-07-01; most recent amendment 2025-07-24.
Status change: Recruiting → Active, Not Recruiting 2024-03-25
Status change: Active, Not Recruiting → Recruiting 2022-07-25
Trial Details
NCT Number NCT04459052
Lead Sponsor Thomas Jefferson University
Conditions Parkinson Disease, Idiopathic Parkinson Disease
Enrollment 50 participants
Start Date 2020-04-30
Primary Completion 2025-04-11 (estimated)
Study Completion 2027-01-08 (estimated)
Updated on ClinicalTrials.gov 2025-07-29